Citicoline and episodic memory: grade C

Limited evidence. Direction: Benefit.

Evidence maturity: Early signalShort-term only

Educational guidance, not medical advice

Why this grade

Rubric condition met: C: results only in older populations (adults 50-85 with age-associated memory complaints) being extrapolated to healthy adults; the larger RCT's positive findings were secondary outcomes

Two randomized placebo-controlled trials in adults aged 50-85 found better memory scores with citicoline: a 12-week industry-funded trial (n=100, 500 mg/day) on secondary episodic and composite memory outcomes, with no statistically significant difference on its primary outcome, and a 1996 trial in which benefit appeared only in a subgroup with relatively inefficient memories identified after analysis, then at 2000 mg/day in a 32-person crossover. EFSA's 2024 claims opinion (cause and effect not established, after reviewing these trials) is regulatory context and does not inform this grade. Evidence is limited to older adults with memory complaints and to 3 months or less, so C rather than B.

How sure are we?

Evidence maturity: Early signal In both supporting RCTs the positive memory results were secondary or in a subgroup identified after analysis.

Tested as: Citicoline (including Cognizin)

Who paid for the studies: Mostly industry-funded
Risk of bias: Some concerns. Nakazaki 2021 primary (Cambridge Brain Sciences score) was null; memory positives secondary.
Trial registry check: Checked, no issue found. NCT03369925 submitted December 7, 2017, before the January 2, 2018 start; reported primary matches the registry.
Outcome measured: A test score, rating scale or performance measure
Who was studied: Older adults only
Doses used in studies: 500-2,000 mg a day
Rules applied: Population cap (logged, no further change): Adults 50-85 with age-associated memory impairment

Could rise: Would move to B with an independent preregistered RCT in healthy adults with memory as the primary outcome, positive.
Could fall: Would move to N with two adequately sized RCTs null on a memory primary.

Science is provisional. This grade reflects the evidence we found as of November 14, 2026. Next review: May 14, 2027.

Maturity sits beside each grade. The grade says what the evidence shows; maturity says how much of it there is and how well it is confirmed.

Established: many trials from several independent teams, including at least one registered in advance
Emerging: two or more trials, or one large registered trial, not yet independently confirmed
Early signal: one trial, small pilots, or results only on secondary outcomes
Mechanistic only: lab, animal or biomarker data, or uncontrolled reports; no controlled human results
Traditional use only: a traditional-use monograph and nothing else

How we grade evidence

Studies this grade rests on

each study this grade rests on, by publication year and design. Solid: effect versus the comparator; half-filled: mixed; hollow: no effect; dashed: result not recorded yet. Larger marks had more participants.

Show the numbers

Study	Year	Design	Participants	Result
Spiers 1996	1996	crossover RCT	95	result not recorded
Nakazaki 2021	2021	RCT	100	result not recorded
EFSA 2024	2024	efsa nda panel scientific opinion on a health claim (article 13(5))	not recorded	result not recorded

'Citicoline' and support of the memory function: Evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006.

EFSA Panel on Nutrition, Novel Foods and Food allergens (NDA), Turck D. 'Citicoline' and support of the memory function: Evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 EFSA J, 2024. PMID 38966137

Result not recorded

Design: EFSA NDA Panel scientific opinion on a health claim (Article 13(5))
Population: Middle-aged or elderly adults with age-associated subjective memory impairment
Funding: EFSA (regulatory opinion; application by Egde Pharma Sp. z o.o.)

Citicoline improves verbal memory in aging.

Spiers PA, Myers D, Hochanadel GS. Citicoline improves verbal memory in aging Arch Neurol, 1996. PMID 8624220

Result not recorded

Design: Randomized, double-blind, placebo-controlled parallel trial (3 months) followed by a crossover study (2 months per arm) in a subgroup
Sample: n = 95
Population: Adults aged 50-85 screened for dementia and memory disorders; crossover in 32 with relatively inefficient memories
Funding: NIMH NIH HHS MH-28783; NCRR NIH HHS MO1-RR-00088 (PubMed GrantList)

Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Nakazaki E, Mah E, Sanoshy K. Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial J Nutr, 2021. PMID 33978188

Result not recorded

Design: Randomized, double-blind, placebo-controlled trial, 12 weeks
Sample: n = 100
Population: Healthy adults aged 50-85 with age-associated memory impairment
Funding: Kyowa Hakko Bio Co., Ltd (sponsor; full text)

Search and history

Search (November 11, 2026): (citicoline[ti] OR CDP-choline[ti]) AND (attention[tiab] OR memory[tiab] OR cognitive[tiab]) AND randomized controlled trial[pt]

November 11, 2026 Graded C (awaiting approval)
November 13, 2026 C to C (approved): Editor sign-off November 13, 2026: grade matches the editor-approved final page
November 14, 2026 C to C (approved) (maturity: early signal): Maturity, bias summary and re-check date added